+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hyperlipidemia Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • PDF Icon

    Report

  • 86 Pages
  • May 2025
  • Region: Global
  • Prof Research
  • ID: 6090494
Description Jump to:
Hyperlipidemia drugs, including statins, PCSK9 inhibitors, and fibric acid derivatives, manage high cholesterol, a key risk factor for cardiovascular disease (CVD), which caused 17.9 million deaths in 2019. The market is driven by high CVD prevalence (33% of adults globally have high cholesterol), an aging population (40% prevalence in those over 60), and lifestyle factors like obesity (424 million obese adults). Novel therapies like inclisiran and bempedoic acid, with 20% improved adherence, and accelerated FDA approvals (15% faster market entry) boost growth. The global hyperlipidemia drugs market is estimated at USD 800-1,300 million in 2025, with a CAGR of 4%-8% through 2030.

Regional Market Trends

  • North America: The U.S. leads with high CVD rates and PCSK9 inhibitor adoption, while Canada focuses on preventive care.
  • Europe: Germany, France, and the UK drive growth with robust lipid-lowering programs.
  • Asia Pacific: China and India see rising demand due to lifestyle changes, with Japan emphasizing novel therapies.
  • Rest of the World: Brazil expands CVD management, while the Middle East addresses metabolic disorders.

Distribution Channel Analysis

  • Hospital Pharmacies: Expected growth of 4.5%-8.5%, driven by PCSK9 inhibitors. Trends focus on specialized care.
  • Online Pharmacies: Projected growth of 5.0%-9.0%, linked to patient convenience. Advances emphasize digital prescriptions.
  • Retail Pharmacies: Anticipated growth of 4.0%-8.0%, covering statins. Trends highlight community access.

Type Analysis

  • Statins: Expected growth of 3.5%-7.5%, valued for efficacy. Trends focus on generic formulations.
  • Bile Acid Sequestrants: Projected growth of 3.0%-7.0%, used in niche cases. Advances emphasize combination therapies.
  • Cholesterol Absorption Inhibitors: Anticipated growth of 3.8%-7.8%, suited for adjunct therapy. Trends highlight oral agents.
  • Fibric Acid Derivatives: Expected growth of 3.2%-7.2%, for triglyceride management. Developments prioritize safety profiles.
  • PCSK9 Inhibitors: Expected growth of 5.5%-9.5%, favored for high-risk patients. Trends focus on siRNA therapies.
  • Combination: Expected growth of 4.2%-8.2%, for comprehensive management. Trends highlight fixed-dose combinations.
  • Miscellaneous: Expected growth of 3.0%-7.0%, covering novel drugs. Developments prioritize non-statin options.

Key Market Players

  • Pfizer: Offers statins for cholesterol management.
  • AstraZeneca: Develops combination therapies.
  • Amgen: Provides PCSK9 inhibitors.
  • Sanofi: Focuses on novel lipid-lowering drugs.
  • Merck: Supplies cholesterol absorption inhibitors.

Porter’s Five Forces Analysis

  • Threat of New Entrants: Moderate, due to high R&D costs, but generics lower barriers.
  • Threat of Substitutes: Moderate, with lifestyle interventions competing, but drugs are primary for severe cases.
  • Bargaining Power of Buyers: High, as generics increase price competition.
  • Bargaining Power of Suppliers: Low, with multiple API providers.
  • Competitive Rivalry: High, with players competing on efficacy and cost.

Market Opportunities and Challenges

Opportunities:

  • Addressing CVD, causing 17.9 million deaths annually.
  • Leveraging an aging population, with 40% cholesterol prevalence.
  • Managing obesity, affecting 424 million adults.
  • Utilizing novel therapies, improving adherence by 20%.
  • Benefiting from accelerated FDA approvals.
  • Expanding preventive care in emerging markets.

Challenges:

  • Price erosion due to generics.
  • Competition from lifestyle interventions.
  • Regulatory delays for novel drugs.
  • High costs of PCSK9 inhibitors limiting access.
  • Patient adherence issues with long-term therapies.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Hyperlipidemia Drug Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Hyperlipidemia Drug Market in North America (2020-2030)
8.1 Hyperlipidemia Drug Market Size
8.2 Hyperlipidemia Drug Market by End Use
8.3 Competition by Players/Suppliers
8.4 Hyperlipidemia Drug Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Hyperlipidemia Drug Market in South America (2020-2030)
9.1 Hyperlipidemia Drug Market Size
9.2 Hyperlipidemia Drug Market by End Use
9.3 Competition by Players/Suppliers
9.4 Hyperlipidemia Drug Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Hyperlipidemia Drug Market in Asia & Pacific (2020-2030)
10.1 Hyperlipidemia Drug Market Size
10.2 Hyperlipidemia Drug Market by End Use
10.3 Competition by Players/Suppliers
10.4 Hyperlipidemia Drug Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Hyperlipidemia Drug Market in Europe (2020-2030)
11.1 Hyperlipidemia Drug Market Size
11.2 Hyperlipidemia Drug Market by End Use
11.3 Competition by Players/Suppliers
11.4 Hyperlipidemia Drug Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Hyperlipidemia Drug Market in MEA (2020-2030)
12.1 Hyperlipidemia Drug Market Size
12.2 Hyperlipidemia Drug Market by End Use
12.3 Competition by Players/Suppliers
12.4 Hyperlipidemia Drug Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Hyperlipidemia Drug Market (2020-2025)
13.1 Hyperlipidemia Drug Market Size
13.2 Hyperlipidemia Drug Market by End Use
13.3 Competition by Players/Suppliers
13.4 Hyperlipidemia Drug Market Size by Type
Chapter 14 Global Hyperlipidemia Drug Market Forecast (2025-2030)
14.1 Hyperlipidemia Drug Market Size Forecast
14.2 Hyperlipidemia Drug Application Forecast
14.3 Competition by Players/Suppliers
14.4 Hyperlipidemia Drug Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Pfizer
15.1.1 Company Profile
15.1.2 Main Business and Hyperlipidemia Drug Information
15.1.3 SWOT Analysis of Pfizer
15.1.4 Pfizer Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
15.2 AstraZeneca
15.2.1 Company Profile
15.2.2 Main Business and Hyperlipidemia Drug Information
15.2.3 SWOT Analysis of AstraZeneca
15.2.4 AstraZeneca Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
15.3 Amgen
15.3.1 Company Profile
15.3.2 Main Business and Hyperlipidemia Drug Information
15.3.3 SWOT Analysis of Amgen
15.3.4 Amgen Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
15.4 Sanofi
15.4.1 Company Profile
15.4.2 Main Business and Hyperlipidemia Drug Information
15.4.3 SWOT Analysis of Sanofi
15.4.4 Sanofi Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
15.5 Merck
15.5.1 Company Profile
15.5.2 Main Business and Hyperlipidemia Drug Information
15.5.3 SWOT Analysis of Merck
15.5.4 Merck Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
15.6 Viatris
15.6.1 Company Profile
15.6.2 Main Business and Hyperlipidemia Drug Information
15.6.3 SWOT Analysis of Viatris
15.6.4 Viatris Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
15.7 Daiichi Sankyo Company
15.7.1 Company Profile
15.7.2 Main Business and Hyperlipidemia Drug Information
15.7.3 SWOT Analysis of Daiichi Sankyo Company
15.7.4 Daiichi Sankyo Company Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
15.8 Esperion Therapeutics
15.8.1 Company Profile
15.8.2 Main Business and Hyperlipidemia Drug Information
15.8.3 SWOT Analysis of Esperion Therapeutics
15.8.4 Esperion Therapeutics Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
15.9 Dr. Reddy’s Laboratories
15.9.1 Company Profile
15.9.2 Main Business and Hyperlipidemia Drug Information
15.9.3 SWOT Analysis of Dr. Reddy’s Laboratories
15.9.4 Dr. Reddy’s Laboratories Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
15.10 Novartis
15.10.1 Company Profile
15.10.2 Main Business and Hyperlipidemia Drug Information
15.10.3 SWOT Analysis of Novartis
15.10.4 Novartis Hyperlipidemia Drug Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Hyperlipidemia Drug Report
Table Data Sources of Hyperlipidemia Drug Report
Table Major Assumptions of Hyperlipidemia Drug Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Hyperlipidemia Drug Picture
Table Hyperlipidemia Drug Classification
Table Hyperlipidemia Drug Applications
Table Drivers of Hyperlipidemia Drug Market
Table Restraints of Hyperlipidemia Drug Market
Table Opportunities of Hyperlipidemia Drug Market
Table Threats of Hyperlipidemia Drug Market
Table COVID-19 Impact For Hyperlipidemia Drug Market
Table Raw Materials Suppliers
Table Different Production Methods of Hyperlipidemia Drug
Table Cost Structure Analysis of Hyperlipidemia Drug
Table Key End Users
Table Latest News of Hyperlipidemia Drug Market
Table Merger and Acquisition
Table Planned/Future Project of Hyperlipidemia Drug Market
Table Policy of Hyperlipidemia Drug Market
Table 2020-2030 North America Hyperlipidemia Drug Market Size
Figure 2020-2030 North America Hyperlipidemia Drug Market Size and CAGR
Table 2020-2030 North America Hyperlipidemia Drug Market Size by Application
Table 2020-2025 North America Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 North America Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 North America Hyperlipidemia Drug Market Size by Type
Table 2020-2030 United States Hyperlipidemia Drug Market Size
Table 2020-2030 Canada Hyperlipidemia Drug Market Size
Table 2020-2030 Mexico Hyperlipidemia Drug Market Size
Table 2020-2030 South America Hyperlipidemia Drug Market Size
Figure 2020-2030 South America Hyperlipidemia Drug Market Size and CAGR
Table 2020-2030 South America Hyperlipidemia Drug Market Size by Application
Table 2020-2025 South America Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 South America Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 South America Hyperlipidemia Drug Market Size by Type
Table 2020-2030 Brazil Hyperlipidemia Drug Market Size
Table 2020-2030 Argentina Hyperlipidemia Drug Market Size
Table 2020-2030 Chile Hyperlipidemia Drug Market Size
Table 2020-2030 Peru Hyperlipidemia Drug Market Size
Table 2020-2030 Asia & Pacific Hyperlipidemia Drug Market Size
Figure 2020-2030 Asia & Pacific Hyperlipidemia Drug Market Size and CAGR
Table 2020-2030 Asia & Pacific Hyperlipidemia Drug Market Size by Application
Table 2020-2025 Asia & Pacific Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Hyperlipidemia Drug Market Size by Type
Table 2020-2030 China Hyperlipidemia Drug Market Size
Table 2020-2030 India Hyperlipidemia Drug Market Size
Table 2020-2030 Japan Hyperlipidemia Drug Market Size
Table 2020-2030 South Korea Hyperlipidemia Drug Market Size
Table 2020-2030 Southeast Asia Hyperlipidemia Drug Market Size
Table 2020-2030 Australia Hyperlipidemia Drug Market Size
Table 2020-2030 Europe Hyperlipidemia Drug Market Size
Figure 2020-2030 Europe Hyperlipidemia Drug Market Size and CAGR
Table 2020-2030 Europe Hyperlipidemia Drug Market Size by Application
Table 2020-2025 Europe Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 Europe Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 Europe Hyperlipidemia Drug Market Size by Type
Table 2020-2030 Germany Hyperlipidemia Drug Market Size
Table 2020-2030 France Hyperlipidemia Drug Market Size
Table 2020-2030 United Kingdom Hyperlipidemia Drug Market Size
Table 2020-2030 Italy Hyperlipidemia Drug Market Size
Table 2020-2030 Spain Hyperlipidemia Drug Market Size
Table 2020-2030 Belgium Hyperlipidemia Drug Market Size
Table 2020-2030 Netherlands Hyperlipidemia Drug Market Size
Table 2020-2030 Austria Hyperlipidemia Drug Market Size
Table 2020-2030 Poland Hyperlipidemia Drug Market Size
Table 2020-2030 Russia Hyperlipidemia Drug Market Size
Table 2020-2030 MEA Hyperlipidemia Drug Market Size
Figure 2020-2030 MEA Hyperlipidemia Drug Market Size and CAGR
Table 2020-2030 MEA Hyperlipidemia Drug Market Size by Application
Table 2020-2025 MEA Hyperlipidemia Drug Key Players Revenue
Table 2020-2025 MEA Hyperlipidemia Drug Key Players Market Share
Table 2020-2030 MEA Hyperlipidemia Drug Market Size by Type
Table 2020-2030 Egypt Hyperlipidemia Drug Market Size
Table 2020-2030 Israel Hyperlipidemia Drug Market Size
Table 2020-2030 South Africa Hyperlipidemia Drug Market Size
Table 2020-2030 Gulf Cooperation Council Countries Hyperlipidemia Drug Market Size
Table 2020-2030 Turkey Hyperlipidemia Drug Market Size
Table 2020-2025 Global Hyperlipidemia Drug Market Size by Region
Table 2020-2025 Global Hyperlipidemia Drug Market Size Share by Region
Table 2020-2025 Global Hyperlipidemia Drug Market Size by Application
Table 2020-2025 Global Hyperlipidemia Drug Market Share by Application
Table 2020-2025 Global Hyperlipidemia Drug Key Vendors Revenue
Figure 2020-2025 Global Hyperlipidemia Drug Market Size and Growth Rate
Table 2020-2025 Global Hyperlipidemia Drug Key Vendors Market Share
Table 2020-2025 Global Hyperlipidemia Drug Market Size by Type
Table 2020-2025 Global Hyperlipidemia Drug Market Share by Type
Table 2025-2030 Global Hyperlipidemia Drug Market Size by Region
Table 2025-2030 Global Hyperlipidemia Drug Market Size Share by Region
Table 2025-2030 Global Hyperlipidemia Drug Market Size by Application
Table 2025-2030 Global Hyperlipidemia Drug Market Share by Application
Table 2025-2030 Global Hyperlipidemia Drug Key Vendors Revenue
Figure 2025-2030 Global Hyperlipidemia Drug Market Size and Growth Rate
Table 2025-2030 Global Hyperlipidemia Drug Key Vendors Market Share
Table 2025-2030 Global Hyperlipidemia Drug Market Size by Type
Table 2025-2030 Hyperlipidemia Drug Global Market Share by Type

Companies Mentioned

  • Pfizer
  • AstraZeneca
  • Amgen
  • Sanofi
  • Merck
  • Viatris
  • Daiichi Sankyo Company
  • Esperion Therapeutics
  • Dr. Reddy’s Laboratories
  • Novartis

Related Topics

Related Reports

Hyperlipidemia Drugs - Global Strategic Business Report - Product Image

Hyperlipidemia Drugs - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Hyperlipidemia Drugs Market by Drug Class, Distribution Channel, End User, Route of Administration, Patient Type, Hyperlipidemia Type - Global Forecast to 2030 - Product Image

Hyperlipidemia Drugs Market by Drug Class, Distribution Channel, End User, Route of Administration, Patient Type, Hyperlipidemia Type - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Hyperlipidemia Drugs Market Report by Drug Type, End User, and Region 2024-2032 - Product Image

Hyperlipidemia Drugs Market Report by Drug Type, End User, and Region 2024-2032

  • Report
  • 146 Pages
  • Global
From
Hyperlipidemia - Pipeline Insight, 2025 - Product Image

Hyperlipidemia - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Hyperlipidemia - Global Clinical Trials Review, 2024 - Product Image

Hyperlipidemia - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 1040 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.